| Name | Title | Contact Details |
|---|
IlluminOss Medical is a privately-held, commercial stage medical device company focused on designing, developing and marketing orthopedic fracture repair products that leverage its proprietary bone stabilization technology, IlluminOss System. This minimally invasive technology allows for fracture fixation through patient specific intramedullary implants. The IlluminOss System utilizes a light-curable polymer, contained within an expandable balloon catheter to achieve bone stabilization. The revolutionary procedure is made through a small percutaneous surgical approach providing patients and clinicians with a fast, patient-specific, method of orthopedic bone stabilization. The company currently markets its products in the EU under a CE Mark for approved clinical applications through both a direct sales force and distribution networks. Founded in 2007, IlluminOss is headquartered in East Providence, RI, and funded by Flare Capital Partners, New Leaf Venture Partners, Tekla Capital, Life Sciences Partners, SR One, Longwood Fund, Excel Venture Management, Pappas Ventures, Mieza Capital and Slater Technology.
Sunoptic Technologies is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MedWiz Pharmacy is a Bardonia, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PureFlora was founded in 2012 by Tivon Sidorsky, MD after a family member’s severe case of C. difficile introduced him to the efficacy of fecal matter transplants (FMT) and the need for a standardized, sanitary, and labor reducing system by which to collect, process, and deliver fecal matter. Recognizing the tremendous opportunity for research and clinical applications for human gut microbiota and the elegant solution proposed by Dr. Sidorsky, veteran medical device executive William L. Mince joined forces with the inventor building the now-patented technology and team that is PureFlora.
Baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.